Diffuse Large B Cell Lymphoma: Updates on Diagnosis and Treatments

8,422
Total downloads
29k
Total views and downloads

Download PDF Download EPUB

Articles

ORIGINAL RESEARCH

Published on 06 Jun 2024

Performance of MYC, BCL2, and BCL6 break-apart FISH in small biopsies with large B-cell lymphoma: a retrospective Cytopathology Hematopathology Interinstitutional Consortium study

Joshua R. Menke
Umut Aypar
Charles D. Bangs
Stephen L. Cook
Srishti Gupta
Robert P. Hasserjian
Christina S. Kong
Oscar Lin
Steven R. Long
7 more
Dita A. Gratzinger

doi 10.3389/fonc.2024.1408238

1,299 views

CASE REPORT

Published on 12 Mar 2024

Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report

Kewei Zhao
Qiuhui Li
Pengye Li
Tao Liu
Xinxiu Liu
Fang Zhu
Liling Zhang

doi 10.3389/fimmu.2024.1303310

1,703 views
1 citation

CLINICAL TRIAL

Published on 26 Feb 2024

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

Lourdes Hontecillas-Prieto
Daniel J. García-Domínguez
Natalia Palazón-Carrión
Alejandro Martín García-Sancho
Esteban Nogales-Fernández
Carlos Jiménez-Cortegana
María L. Sánchez-León
Silvia Silva-Romeiro
Rocío Flores-Campos
20 more
Luis de la Cruz-Merino

doi 10.3389/fimmu.2024.1293931

1,733 views
2 citations

ORIGINAL RESEARCH

Published on 12 Feb 2024

Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study

Yu Ri Kim
Ho Jin Shin
Ho-Young Yhim
Deok-Hwan Yang
Yong Park
Ji Hyun Lee
Won-Sik Lee
Young Rok Do
Yeung-Chul Mun
1 more
Jin Seok Kim

doi 10.3389/fonc.2024.1363385

1,221 views

BRIEF RESEARCH REPORT

Published on 08 Feb 2024

Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma

A. John Callegari
Josephine Tsang
Stanley Park
Deanna Swartzfager
Sheena Kapoor
Kevin Choy
Sungwon Lim

doi 10.3389/fonc.2024.1304144

2,521 views
3 citations

ORIGINAL RESEARCH

Published on 01 Feb 2024

A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma

Jeong-Yeon Cho
Suk-Chan Jang
Dong-Won Kang
Eui-Kyung Lee
Hyein Koh
Dok Hyun Yoon
Mi-Hai Park

doi 10.3389/fonc.2024.1282323

1,930 views
1 citation

ORIGINAL RESEARCH

Published on 12 Dec 2023

Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

ChaoFeng Zhang
Qi Lin
ChunTuan Li
Yang Qiu
JingYu Chen
XiongPeng Zhu

doi 10.3389/fimmu.2023.1277695

1,620 views
6 citations

ORIGINAL RESEARCH

Published on 14 Nov 2023

EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas

Alice Turdo
Miriam Gaggianesi
Caterina D’Accardo
Gaetana Porcelli
Sebastiano Di Bella
Dario Cricchio
Irene Pillitteri
Rossana Porcasi
Melania Lo Iacono
6 more
Matilde Todaro

doi 10.3389/fimmu.2023.1266265

1,667 views
2 citations

ORIGINAL RESEARCH

Published on 28 Sep 2023

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

Katrin Schoenfeld
Julia Harwardt
Jan Habermann
Adrian Elter
Harald Kolmar

doi 10.3389/fimmu.2023.1258700

3,988 views
5 citations

SYSTEMATIC REVIEW

Published on 20 Jan 2023

The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis

Mei Lin
Shupei Ma
Lingling Sun
Zhiqiang Qin

doi 10.3389/fonc.2022.1094400

1,970 views
10 citations

ORIGINAL RESEARCH

Published on 17 Nov 2022

Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma

Tao Guan
Min Zhang
Xiaolan Liu
Jing Li
Beibei Xin
Yanxin Ren
Yuchao Yang
Hui Wang
Mengjing Zhao
4 more
Liping Su

doi 10.3389/fonc.2022.1003957

2,487 views
5 citations

ORIGINAL RESEARCH

Published on 31 Oct 2022

Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma

Karolina Piechna
Aleksandra Żołyniak
Ewa Jabłońska
Monika Noyszewska-Kania
Maciej Szydłowski
Bartłomiej Żerek
Maria Kulecka
Izabela Rumieńczyk
Michał Mikula
Przemysław Juszczyński

doi 10.3389/fonc.2022.1048741

1,715 views
4 citations

Share on

Frontiers in Oncology

Hematologic Malignancies

Impact

29kTopic views
19kArticle views
8,422Article downloads

View impact

Articles

Performance of MYC, BCL2, and BCL6 break-apart FISH in small biopsies with large B-cell lymphoma: a retrospective Cytopathology Hematopathology Interinstitutional Consortium study

Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study

Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma

A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma

Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis

Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma

Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma

Frontiers in Oncology

Hematologic Malignancies